|
|
 |
|
Viewing report
|
|
|
|
High Content Screening (HCS): An Industry Analysis
Drug and Market Development Publishing, March 2006, Pages: 220
'High Content Screening (HCS): An Industry Analysis' is focused on an emerging and key segment of the life science tools and technology space - high content analysis. High content biology has various ramifications in life science research, academic research, drug discovery, and development. This report focuses on this emerging space, the major technologies and products, and its market landscape through both a qualitative and quantitative analysis. In addition to describing the technical aspects of high-content screening (HCS) in this report, a thorough market analysis is presented complemented by primary data from a proprietary survey conducted on this topic.
HCS and secondary screening are an outgrowth of high-throughput screening that have commanded much attention and resources in the pharmaceutical and biotechnology companies over the past decade. Currently, the challenge has moved towards analyses of sub-cellular organization, morphology, and these are major facets of HCS.
Receive answers to crucial questions in this area such as:
- What are the strategic market opportunities for the high-content analysis/screening space?
- What is the size and growth rate of the High-Content Screening and Analysis market?
- What are the challenges and bottlenecks in the HCS space?
- Who are the key players in the HCS marketplace?
- What are the major products available today in the HCS marketplace?
About the Author
Dr. Enal Razvi is currently a biotechnology business development consultant based in the San Francisco Bay Area. In this capacity, Dr. Razvi analyzes a number of different market spaces in biotechnology, and assists start-up companies in business development, sales, marketing, and commercialization operations in the San Francisco Bay Area. Previously, Dr. Razvi served as Vice President of Business Development at DiscoveRx Corporation in Fremont, California. Before DiscoveRx, at LJL BioSystems (Sunnyvale, CA), Dr. Razvi served as Senior Director of Business Development and played a major role in developing LJL BioSystems' SNP genotyping business. Subsequent to the acquisition of LJL BioSystems by Molecular Devices Corporation, Dr. Razvi ran Molecular Devices' Genomics business. Prior to LJL, while at Frost & Sullivan, Dr. Razvi served as Director of their Drug Discovery Consulting business. Dr. Razvi holds a doctorate in biomedical sciences from the University of Massachusetts Medical School, and completed post-doctoral work at The Rockefeller University in New York and at Harvard Medical School.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
High Throughput Screening
High Content Screening: Science, Techniques and Applications
Cell-Based Assays for Drug Discovery
Drug Discovery Tools for High-Content Analysis
U.S. High Content Screening Markets
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery
HCA, Inc. - Strategic Analysis Review
hERG Screening
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery
Toxicity Screening 2009
HCA, Inc. - SWOT Analysis - SWOT Analysis
Financial Analysis - HCA Inc.
|
|
|
|
